Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for Cell and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a highly selective, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC₅₀ values of approximately 140 nM and a K_i of 300 nM, respectively, under standard in vitro kinase conditions (APExBIO). It demonstrates over 200-fold selectivity against related kinases, such as PKC and MLCK, minimizing off-target effects (DZNEP). Y-27632 disrupts Rho-mediated stress fiber formation, modulates cell cycle progression from G1 to S phase, and inhibits cytokinesis (Khosrowpour et al. 2025). In stem cell applications, it enhances cell survival and engraftment by preventing apoptosis during dissociation (Epitopeptide). The compound is widely used in cancer biology, stem cell research, and regenerative medicine for its robust, reproducible effect on cytoskeletal dynamics (INCA-6).

Biological Rationale

ROCK1 and ROCK2 are serine/threonine kinases downstream of the small GTPase RhoA. They regulate actin cytoskeleton organization, cellular contractility, migration, and proliferation. Dysregulated Rho/ROCK signaling is implicated in tumor invasion, fibrosis, and abnormal smooth muscle contractility. Selective inhibition of ROCK kinases has emerged as a strategy to dissect cytoskeletal dynamics, modulate cell cycle transitions, and explore therapeutic avenues in oncology and regenerative medicine (Khosrowpour et al. 2025). Y-27632 dihydrochloride enables precise, reversible inhibition of ROCK-mediated pathways, facilitating both fundamental and translational research.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a small-molecule inhibitor that selectively binds the ATP-binding site within the catalytic domains of ROCK1 and ROCK2. This inhibits kinase activity with an IC₅₀ of ~140 nM for ROCK1 and a K_i of 300 nM for ROCK2. Selectivity is over 200-fold higher than for kinases such as PKC, cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK) under standard assay conditions. Inhibition results in decreased phosphorylation of downstream substrates, including myosin light chain (MLC) and LIM kinase, leading to disassembly of actin stress fibers and focal adhesions. This disruption impedes cell contractility, abrogates cytokinesis, and modulates cell cycle progression from G1 to S phase (Khosrowpour et al. 2025). Y-27632 is cell-permeable and acts rapidly in vitro, with effects observable within 30–60 minutes of exposure at concentrations of 10–50 μM (APExBIO).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a K_i of 300 nM in recombinant kinase assays (APExBIO).
• It demonstrates >200-fold selectivity relative to PKC, PKA, MLCK, and PAK under standardized conditions (DZNEP).
• Y-27632 reduces Rho-mediated actin stress fiber formation within 30–60 min in cultured cells at 10–50 μM concentrations (Epitopeptide).
• In hiPSC-derived myogenic progenitor cultures, Y-27632 enhances cell survival and post-transplant engraftment of satellite cells in mouse models (Khosrowpour et al. 2025).
• In vivo, Y-27632 reduces tumor invasion and metastatic spread in mouse cancer models when administered at 30 mg/kg intraperitoneally daily for 14 days (INCA-6).
• The compound is soluble to ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25°C; warming to 37°C or sonication increases dissolution rates (APExBIO).

Applications, Limits & Misconceptions

Applications

• Cytoskeletal research: Y-27632 is a reference inhibitor for dissecting Rho/ROCK signaling in actin dynamics and stress fiber formation (Epitopeptide).
• Stem cell biology: Enhances survival of dissociated hiPSCs and hESCs during passaging and cryopreservation (Khosrowpour et al. 2025).
• Cancer research: Reduces tumor cell invasion, metastasis, and promotes more physiological cell proliferation profiles (DZNEP).
• Proliferation assays: Used to study cell cycle transitions and cytokinesis in both normal and transformed cells.

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor; it is highly selective for ROCK1/2 and does not inhibit PKC, PKA, MLCK, or PAK at relevant concentrations.
• Chronic, high-dose use may cause off-target effects; dosing should be titrated to minimize non-specific inhibition.
• Y-27632 does not induce myogenic differentiation itself; it supports survival and proliferation but does not direct lineage fate (Khosrowpour et al. 2025).
• Long-term storage of reconstituted solutions at room temperature is not recommended; activity declines above -20°C or with repeated freeze-thaw cycles (APExBIO).
• In vivo efficacy and dosing regimens require optimization for species, tissue, and experimental endpoint.

This article extends the mechanistic focus outlined in "Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for ..." by providing updated in vivo benchmarks and clarifying application boundaries in stem cell workflows. It also updates translational applications compared to "Y-27632 Dihydrochloride: Innovations in ROCK Inhibition f...", which emphasized extracellular vesicle dynamics.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or below. Stock solutions are typically prepared in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL), with gentle heating to 37°C or sonication to ensure complete dissolution. Working solutions are typically used at 10–50 μM for in vitro assays. For stem cell passaging, 10 μM is commonly added to culture medium for 24–48 hours post-dissociation (Khosrowpour et al. 2025). In vivo, dosing regimens vary by model and endpoint; for tumor invasion studies, daily intraperitoneal injections of 30 mg/kg are reported (INCA-6). Solutions should not be stored long-term above -20°C. For detailed protocol guidance, reference the manufacturer's page for the A3008 kit (APExBIO).

Conclusion & Outlook

Y-27632 dihydrochloride is a gold-standard, selective ROCK1/2 inhibitor for the study of cytoskeletal regulation, cell proliferation, and cancer invasion. It enables highly reproducible experimental modulation of the Rho/ROCK pathway across stem cell, cancer, and regenerative models. While its primary mechanism is well-characterized, ongoing research continues to reveal new applications and boundaries. Users are advised to optimize dosing and storage for their specific workflow, and to consult recent peer-reviewed literature for best practices. For comprehensive background and ordering, visit the APExBIO Y-27632 dihydrochloride product page.